PT Biometrik Riset Indonesia Successfully Participates in CPHI Korea 2026

Writer & Editor: Canaya Vania Rehansha

Seoul, August 2026 – PT Biometrik Riset Indonesia has successfully concluded its participation in CPHI Korea 2026, held from 25–27 August 2026 at COEX, Seoul, South Korea. The event provided an important opportunity for Biometrik to strengthen its presence in the international pharmaceutical industry and connect with pharmaceutical companies and potential partners from various countries.

Throughout the exhibition, the Biometrik team welcomed visitors and industry professionals at its booth, where the company introduced its services and capabilities in conducting Bioavailability/Bioequivalence (BA/BE) studies and bioanalytical services. The event also became a valuable platform for exchanging insights, exploring potential collaborations, and building new connections with international pharmaceutical industry stakeholders.

One of the highlights of Biometrik's participation was the seminar session delivered by Andi Darmawan, Head of Technical Operation of PT Biometrik Riset Indonesia, entitled “Bioequivalence Studies: Practical Insights from a Leading Contract Research Organization in Indonesia.” The presentation provided practical insights into the implementation of bioequivalence studies and shared Biometrik's experience and capabilities as a Contract Research Organization (CRO) from Indonesia.

Through its participation in CPHI Korea 2026, PT Biometrik Riset Indonesia continues its commitment to expanding international collaboration and introducing Indonesia's capabilities in the field of pharmaceutical research to the global market.

The successful participation in this event marks another meaningful step for Biometrik in strengthening its international network and exploring future opportunities for collaboration with pharmaceutical industry partners worldwide.

PT Biometrik Riset Indonesia would like to express its appreciation to everyone who visited our booth, attended our seminar session, and shared valuable discussions throughout CPHI Korea 2026. We look forward to building meaningful collaborations and meeting our partners again at future international pharmaceutical events.